Relay Therapeutics Inc

Relay Therapeutics, a Nasdaq‑listed biotech, is chasing breakthrough cancer drugs amid volatile stock swings and a negative P/E. Investors weigh its $2.7 bn cap, high‑potential pipeline and U.S.‑centric trials against R&D‑heavy risks and limited glo…

Relay Therapeutics, a biotech company based in Cambridge, Massachusetts, is dedicated to developing innovative cancer treatments through cutting-edge science and technology.

Relay Therapeutics, a biotech company, will participate in two investor conferences in June to discuss its strategic direction and drug development pipeline.

Relay Therapeutics Inc. is navigating market volatility while continuing to develop innovative cancer treatments, with a focus on advancing its proprietary drug development platform and strategic partnerships.